A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

Starting soon · Phase 1 · Has a placebo group

Conditions studied: HIV -1 Infection

In brief

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.

Key facts

Study ID

NCT07698600

Run by

BioNTech SE

People needed

126

Starts

2026-07-01

Expected to finish

2028-01-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.